AG881
Total Payments
$258,452
Transactions
7
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $258,452 | 7 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $258,452 | 7 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation | Servier BioInnovation | $258,452 | 0 |
Top Doctors Receiving Payments for AG881
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | San Francisco, CA | $258,452 | 7 |
Ad
Manufacturing Companies
- Servier BioInnovation $258,452
Product Information
- Type Drug
- Total Payments $258,452
- Total Doctors 0
- Transactions 7
About AG881
AG881 is a drug associated with $258,452 in payments to 0 healthcare providers, recorded across 7 transactions in the CMS Open Payments database. The primary manufacturer is Servier BioInnovation.
Payment data is available from 2024 to 2024. In 2024, $258,452 was paid across 7 transactions to 0 doctors.
The most common payment nature for AG881 is "Unspecified" ($258,452, 100.0% of total).
AG881 is associated with 1 research study, including "Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation" ($258,452).